奥司他韦是当前抗流感治疗中最成功的神经氨酸酶(NA)抑制剂之一。 NA 的 150 个空腔被确定为一个额外的结合袋,并且根据羧酸奥司他韦 ( OC ) 与 NA 复合物的结构信息,设计了新型 NA 抑制剂来占据 150 个空腔。本研究合成了一系列含有吡唑部分的OC的C-5-NH 2 -酰基衍生物。几种衍生物对 NA 表现出显着的抑制活性。此外,计算机ADME评估表明,该衍生物具有类似药物的特性,比OC具有更高的口服吸收率和更大的细胞渗透性。此外,分子对接研究表明,衍生物与 NA 酶活性位点和 150 腔相互作用,正如预期的那样。研究结果为OC的进一步结构优化提供了有用的信息。
The invention relates to isoxazolo[5,4-b]pyridine compounds of formula (I), to the agriculturally useful salts of isoxazolo[5,4-b]pyridine compounds of formula (I), and to their use as herbicides.
The invention relates to isoxazolo[5,4-b]pyridine compounds of formula (I), to the agriculturally useful salts of isoxazolo[5,4-b]pyridine compounds of formula (I), and to their use as herbicides.
[EN] APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'APELINE ET LEURS MÉTHODES D'UTILISATION
申请人:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
公开号:WO2019032720A1
公开(公告)日:2019-02-14
Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Synthesis, Acaricidal Activity, and Structure–Activity Relationships of Pyrazolyl Acrylonitrile Derivatives
作者:Haibo Yu、Yan Cheng、Man Xu、Yuquan Song、Yanmei Luo、Bin Li
DOI:10.1021/acs.jafc.6b04221
日期:2016.12.28
novel pyrazolyl acrylonitrile derivatives was designed, targeting Tetranychus cinnabarinus, and synthesized. Their structures were identified by combination of 1H NMR, 13C NMR, and MS spectra. The structures of compounds 18 and 19 were further confirmed by X-ray diffraction. Extensive greenhouse bioassays indicated that compound 19 exhibits excellent acaricidal activity against all developmental stages
设计并合成了一系列新颖的吡唑基丙烯腈衍生物,并以朱砂叶螨(Tetranychus cinnabarinus)为靶标。它们的结构通过1 H NMR,13 C NMR和MS光谱的组合来鉴定。化合物18和19的结构通过X射线衍射进一步证实。大量的温室生物测定表明,化合物19对朱砂毛虫的所有发育阶段均表现出优异的杀螨活性,优于商品化的嘧菌草醚和螺二氯芬。结果表明,化合物19的急性毒性对哺乳动物来说是相当低的。还讨论了结构与活动之间的关系。
The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.